GSK's Arexvy vaccine for adults 18+ gets EMA review
Ticker: GLAXF · Form: 6-K · Filed: Jun 13, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jun 13, 2025 |
| Risk Level | low |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-review, vaccine, expansion
Related Tickers: GSK
TL;DR
EMA reviewing GSK's Arexvy for younger adults (18+), decision H1 2026.
AI Summary
GSK plc announced on June 13, 2025, that the European Medicines Agency (EMA) has accepted for regulatory review its respiratory syncytial virus (RSV) vaccine, Arexvy, for adults aged 18 and older. A regulatory decision is anticipated in the first half of 2026.
Why It Matters
This expansion of Arexvy's indication could significantly broaden its market reach, potentially increasing revenue for GSK if approved.
Risk Assessment
Risk Level: low — This filing is an update on a regulatory review process, which is standard for pharmaceutical companies and carries inherent but manageable risks.
Key Numbers
- 18+ — Age group for Arexvy review (Expansion of indication for GSK's RSV vaccine)
Key Players & Entities
- GSK plc (company) — Registrant
- Arexvy (product) — RSV vaccine
- European Medicines Agency (EMA) (company) — Regulatory body
- June 13, 2025 (date) — Announcement date
- H1 2026 (date) — Anticipated decision date
FAQ
What is the specific indication for Arexvy that is under review by the EMA?
The EMA is reviewing Arexvy for adults aged 18 years and older for the prevention of RSV.
When is GSK expecting a decision from the EMA regarding Arexvy's expanded use?
GSK anticipates a regulatory decision in the first half of 2026 (H1 2026).
What is the filing type and date?
This is a Form 6-K filed on June 13, 2025.
What is the ticker symbol for GSK plc on the NYSE?
The filing mentions GSK plc (LSE/NYSE: G), implying G is the NYSE ticker, though it's cut off.
Has GSK plc previously changed its name?
Yes, GSK plc was formerly known as GlaxoSmithKline PLC, with a name change date of January 5, 2001.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 13, 2025 regarding GSK plc (GLAXF).